As of 2025-12-18, the EV/EBITDA ratio of Kala Pharmaceuticals Inc (KALA) is 0.11. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KALA's latest enterprise value is -4.70 mil USD. KALA's TTM EBITDA according to its financial statements is -42.64 mil USD. Dividing these 2 quantities gives us the above KALA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-12-17 | 0.11 |
| 2025-12-16 | 0.12 |
| 2025-12-15 | 0.11 |
| 2025-12-12 | 0.09 |
| 2025-12-11 | 0.08 |
| 2025-12-10 | 0.06 |
| 2025-12-09 | 0.06 |
| 2025-12-08 | 0.04 |
| 2025-12-05 | 0.02 |
| 2025-12-04 | 0.01 |
| 2025-12-03 | 0.02 |
| 2025-12-02 | -0.03 |
| 2025-12-01 | -0.09 |
| 2025-11-28 | 0.01 |
| 2025-11-26 | 0.02 |
| 2025-11-25 | 0.10 |
| 2025-11-24 | 0.10 |
| 2025-11-21 | 0.10 |
| 2025-11-20 | 0.09 |
| 2025-11-19 | 0.10 |
| 2025-11-18 | 0.08 |
| 2025-11-17 | 0.08 |
| 2025-11-14 | 0.08 |
| 2025-11-13 | 0.09 |
| 2025-11-12 | 0.07 |
| 2025-11-11 | 0.07 |
| 2025-11-10 | 0.07 |
| 2025-11-07 | 0.08 |
| 2025-11-06 | 0.07 |
| 2025-11-05 | 0.06 |
| 2025-11-04 | 0.07 |
| 2025-11-03 | 0.06 |
| 2025-10-31 | 0.06 |
| 2025-10-30 | 0.06 |
| 2025-10-29 | 0.05 |
| 2025-10-28 | 0.04 |
| 2025-10-27 | 0.05 |
| 2025-10-24 | 0.05 |
| 2025-10-23 | 0.06 |
| 2025-10-22 | 0.05 |
| 2025-10-21 | 0.02 |
| 2025-10-20 | 0.01 |
| 2025-10-17 | -0.09 |
| 2025-10-16 | -0.11 |
| 2025-10-15 | -0.12 |
| 2025-10-14 | -0.14 |
| 2025-10-13 | -0.14 |
| 2025-10-10 | -0.12 |
| 2025-10-09 | -0.15 |
| 2025-10-08 | -0.16 |